{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:56:33Z","timestamp":1793066193389,"version":"4.5.0"},"reference-count":180,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Glioblastoma (GBM) is the most common and aggressive primary malignancy of the central nervous system, marked by profound metabolic reprogramming that promotes growth, invasion, and therapeutic resistance. This review examines metabolic adaptations that sustain GBM progression and summarizes current and emerging strategies that target these pathways. GBM cells display increased aerobic glycolysis, glutaminolysis, lipid and cholesterol synthesis, and mitochondrial remodeling. These processes are regulated by oncogenic alterations such as EGFR amplification, PTEN loss, and HIF-1\u03b1 stabilization, which allow tumor cells to thrive in hypoxic and nutrient-poor environments. Accumulation of lactate further supports metabolic flexibility and promotes an immunosuppressive microenvironment. Recent studies have focused on exploiting these metabolic vulnerabilities through dietary, pharmacologic, and oxygen-modulating interventions. The ketogenic diet has been explored as an adjuvant therapy to reduce glucose availability and enhance treatment sensitivity. Pharmacologic approaches include inhibition of key metabolic enzymes such as hexokinase 2, pyruvate kinase M2, pyruvate dehydrogenase kinase, and glutaminase. Additional strategies aim to disrupt mitochondrial function through VDAC1 blockade or to reduce tumor hypoxia using hypoxia-activated prodrugs, hyperbaric oxygen therapy, and oxygen-transporting agents. Preclinical findings suggest these approaches can suppress tumor proliferation and improve responsiveness to radiation and chemotherapy, although clinical evidence remains limited. Combining metabolic interventions with standard therapies may help overcome GBM\u2019s intrinsic resistance and metabolic plasticity. Overall, the review highlights metabolism as a key determinant of GBM pathophysiology and a promising target for therapeutic innovation, emphasizing the importance of continued translational research to identify and exploit context-specific metabolic vulnerabilities in this highly lethal disease.<\/jats:p>","DOI":"10.3389\/fonc.2025.1712576","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T05:25:59Z","timestamp":1765344359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Metabolism of glioblastoma: a review of metabolic adaptations and metabolic therapeutic interventions"],"prefix":"10.3389","volume":"15","author":[{"given":"James","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Kafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Verbrugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Bakke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain Malignancies in adults: A review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro-Oncol. 26 vi1\u2013vi85"},{"key":"B3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-020-03451-6","article-title":"Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis","volume":"147","author":"Marenco-Hillembrand","year":"2020","journal-title":"J Neurooncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cancers17010146","article-title":"Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes","volume":"17","author":"Sipos","year":"2025","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00476","article-title":"Key clinical principles in the management of glioblastoma","volume":"19","author":"Kotecha","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00286","article-title":"A meta-analysis of survival outcomes following reoperation in recurrent glioblastoma: time to consider the timing of reoperation","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5603\/RPOR.a2022.0113","article-title":"Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study","volume":"27","author":"Mohammed","year":"2022","journal-title":"Rep Pract Oncol Radiother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1038\/s41598-020-68011-4","article-title":"Longer-term (\u2265\u20092 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis","volume":"10","author":"Poon","year":"2020","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/pharmaceutics15030928","article-title":"Highlighted advances in therapies for difficult-to-treat brain tumours such as glioblastoma","volume":"15","author":"Cruz","year":"2023","journal-title":"Pharmaceutics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.3390\/ijms25115774","article-title":"Revolutionizing glioblastoma treatment: A comprehensive overview of modern therapeutic approaches","volume":"25","author":"Sadowski","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3390\/cancers15072116","article-title":"Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM)","volume":"15","author":"Yalamarty","year":"2023","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/ijms26020669","article-title":"The impact of metabolic rewiring in glioblastoma: the immune landscape and therapeutic strategies","volume":"26","author":"Vijayanathan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41419-018-1195-4","article-title":"Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM","volume":"9","author":"Przystal","year":"2018","journal-title":"Cell Death Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.3101","article-title":"High-capacity glycolytic and mitochondrial oxidative metabolisms mediate the growth ability of glioblastoma","volume":"47","author":"Kim","year":"2015","journal-title":"Int J Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7150\/thno.53506","article-title":"Beyond glucose: alternative sources of energy in glioblastoma","volume":"11","author":"Caniglia","year":"2021","journal-title":"Theranostics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.3390\/cells11192956","article-title":"Therapeutic drug-induced metabolic reprogramming in glioblastoma","volume":"11","author":"Nguyen","year":"2022","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.5c02536","article-title":"Metabolic hijacking: an MOF-based nanoprogrammer overcomes drug resistance in glioblastoma","volume":"25","author":"Wan","year":"2025","journal-title":"Nano Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq187","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism","volume":"102","author":"Reitman","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1106-9","article-title":"What do we know about IDH1\/2 mutations so far, and how do we use it","volume":"125","author":"Horbinski","year":"2013","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M402260200","article-title":"Cytosolic NADP+-dependent isocitrate dehydrogenase plays a key role in lipid metabolism","volume":"279","author":"Koh","year":"2004","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a040550","article-title":"NADPH-the forgotten reducing equivalent","volume":"13","author":"Chandel","year":"2021","journal-title":"Cold Spring Harb. Perspect Biol 13 a040550"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5114\/wo.2018.82642","article-title":"The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas","volume":"22","author":"Reiter-Brennan","year":"2018","journal-title":"Contemp. Oncol Poznan Pol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.06.023","article-title":"Hypoxia induces production of L-2-hydroxyglutarate","volume":"22","author":"Intlekofer","year":"2015","journal-title":"Cell Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3390\/cells10092345","article-title":"& Yang, C. D-2-hydroxyglutarate in glioma biology","volume":"10","author":"Chou","year":"2021","journal-title":"Cells"},{"key":"B30","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.ymgmr.2023.100979","article-title":"Glutaric aciduria and L-2-hydroxyglutaric aciduria: Clinical and molecular findings of 35 patients from Turkey","volume":"36","author":"Bozaci","year":"2023","journal-title":"Mol Genet Metab Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9706-2","article-title":"Hydroxyglutaric aciduria and Malignant brain tumor: a case report and literature review","volume":"91","author":"Aghili","year":"2009","journal-title":"J Neurooncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2016","journal-title":"Neuro-Oncol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-04172-8","article-title":"DNA damage in IDH-mutant gliomas: mechanisms and clinical implications","volume":"162","author":"Shi","year":"2023","journal-title":"J Neurooncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha","volume":"324","author":"Zhao","year":"2009","journal-title":"Science"},{"key":"B36","article-title":"R132H mutation in IDH1 gene is associated with increased tumor HIF1-alpha and serum VEGF levels in primary glioblastoma multiforme","volume":"47","author":"Yalaza","year":"2017","journal-title":"Ann Clin Lab Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2014.9.FOCUS14496","article-title":"Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma","volume":"37","author":"Womeldorff","year":"2014","journal-title":"Neurosurg Focus"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/cancers11091279","article-title":"Ultra-mutation in IDH wild-type glioblastomas of patients younger than 55 years is associated with defective mismatch repair, microsatellite instability, and giant cell enrichment","volume":"11","author":"Barresi","year":"2019","journal-title":"Cancers"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851704001115","article-title":"Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis","volume":"7","author":"Kaur","year":"2005","journal-title":"Neuro-Oncol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1101\/gad.14.4.391","article-title":"Loss of PTEN facilitates HIF-1-mediated gene expression","volume":"14","author":"Zundel","year":"2000","journal-title":"Genes Dev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"114204","DOI":"10.1016\/j.biopha.2022.114204","article-title":"Progress in targeting PTEN\/PI3K\/Akt axis in glioblastoma therapy: Revisiting molecular interactions","volume":"158","author":"Hashemi","year":"2023","journal-title":"Biomed Pharmacother. Biomedecine Pharmacother"},{"key":"B42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0065-230X(09)02002-8","article-title":"PI3K\/PTEN signaling in angiogenesis and tumorigenesis","volume":"102","author":"Jiang","year":"2009","journal-title":"Adv Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1215\/15228517-2008-081","article-title":"EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors","volume":"11","author":"Li","year":"2009","journal-title":"Neuro-Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.02.019","article-title":"Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis","volume":"9","author":"Phillips","year":"2006","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0510","article-title":"Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition","volume":"21","author":"Xu","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1038\/s41467-024-46971-9","article-title":"Endocytic vesicles act as vehicles for glucose uptake in response to growth factor stimulation","volume":"15","author":"Tsutsumi","year":"2024","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2460","article-title":"Proliferation-independent control of tumor glycolysis by PDGFR-mediated AKT activation","volume":"73","author":"Ran","year":"2013","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1038\/s41598-018-24046-2","article-title":"Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion","volume":"8","author":"Wood","year":"2018","journal-title":"vitro. Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.12.015","article-title":"Inflammatory landscape of human brain tumors reveals an NF\u03baB dependent cytokine pathway associated with mesenchymal glioblastoma","volume":"390","author":"Zanotto-Filho","year":"2017","journal-title":"Cancer Lett"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg\u2019s contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/metabo11100668","article-title":"Metabolic tumor microenvironment characterization of contrast enhancing brain tumors using physiologic MRI","volume":"11","author":"Stadlbauer","year":"2021","journal-title":"Metabolites"},{"key":"B54","doi-asserted-by":"publisher","first-page":"17633","DOI":"10.3390\/ijms242417633","article-title":"Role of glycolytic and glutamine metabolism reprogramming on the proliferation, invasion, and apoptosis resistance through modulation of signaling pathways in glioblastoma","volume":"24","author":"Trejo-Solis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-092910-154237","article-title":"Aerobic glycolysis: meeting the metabolic requirements of cell proliferation","volume":"27","author":"Lunt","year":"2011","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1522392","article-title":"Targeting glycolysis: exploring a new frontier in glioblastoma therapy","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.06.092","article-title":"Lactic acid induces lactate transport and glycolysis\/OXPHOS interconversion in glioblastoma","volume":"503","author":"Duan","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964898","article-title":"Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41467-024-46193-z","article-title":"Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression","volume":"15","author":"Khan","year":"2024","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"948098","DOI":"10.1155\/2012\/948098","article-title":"Macrophages in tumor microenvironments and the progression of tumors","volume":"2012","author":"Hao","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi8602","article-title":"Lactate supports a metabolic-epigenetic link in macrophage polarization","volume":"7","author":"Noe","year":"2021","journal-title":"Sci Adv"},{"key":"B62","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bpa.12194","article-title":"MIF receptor CD74 is restricted to microglia\/macrophages, associated with a M1-polarized immune milieu and prolonged patient survival in gliomas","volume":"25","author":"Zeiner","year":"2015","journal-title":"Brain Pathol Zurich Switz"},{"key":"B63","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.immuni.2024.01.019","article-title":"Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells","volume":"57","author":"Ding","year":"2024","journal-title":"Immunity"},{"key":"B64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and cellular functions of CTLA-4","volume":"1248","author":"Van Coillie","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3390\/cancers15072183","article-title":"Biosynthesis and significance of fatty acids, glycerophospholipids, and triacylglycerol in the processes of glioblastoma tumorigenesis","volume":"15","author":"Korbecki","year":"2023","journal-title":"Cancers"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169566","article-title":"Inhibition of acetyl-coA carboxylase 1 (ACC1) and 2 (ACC2) reduces proliferation and de novo lipogenesis of EGFRvIII human glioblastoma cells","volume":"12","author":"Jones","year":"2017","journal-title":"PLoS One"},{"key":"B68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3892\/ijo.2025.5779","article-title":"Knockdown of ACC1 promotes migration and invasion of U251 glioma cells by epigenetically suppressing SDH","volume":"67","author":"Wei","year":"2025","journal-title":"Int J Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14740","article-title":"Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma","volume":"8","author":"Kambach","year":"2017","journal-title":"Oncotarget"},{"key":"B70","doi-asserted-by":"publisher","first-page":"15458","DOI":"10.1038\/s41598-019-51865-8","article-title":"LXR\u03b2 controls glioblastoma cell growth, lipid balance, and immune modulation independently of ABCA1","volume":"9","author":"Patel","year":"2019","journal-title":"Sci Rep"},{"key":"B71","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/neuonc\/noad233","article-title":"Cholesterol homeostasis confers glioma Malignancy triggered by hnRNPA2B1-dependent regulation of SREBP2 and LDLR","volume":"26","author":"Zhang","year":"2024","journal-title":"Neuro-Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"154176","DOI":"10.1016\/j.prp.2022.154176","article-title":"SREBP2\/Rab11s\/GLUT1\/6 network regulates proliferation and migration of glioblastoma","volume":"240","author":"Cheng","year":"2022","journal-title":"Pathol Res Pract"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709747104","article-title":"Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis","volume":"104","author":"DeBerardinis","year":"2007","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3102","article-title":"Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity","volume":"23","author":"Oizel","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae222","article-title":"Glutamate dehydrogenase 1-catalytic glutaminolysis feedback activates EGFR\/PI3K\/AKT pathway and reprograms glioblastoma metabolism","volume":"27","author":"Yang","year":"2025","journal-title":"Neuro-Oncol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11680","article-title":"Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma","volume":"7","author":"Vartanian","year":"2016","journal-title":"Oncotarget"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2017.02.009","article-title":"Role of AHR and HIF-1\u03b1 in glioblastoma metabolism","volume":"28","author":"Gabriely","year":"2017","journal-title":"Trends Endocrinol Metab TEM"},{"key":"B78","doi-asserted-by":"publisher","first-page":"12608","DOI":"10.3390\/ijms222212608","article-title":"Hypoxia: the cornerstone of glioblastoma","volume":"22","author":"Dom\u00e8nech","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.164","article-title":"mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3","volume":"34","author":"Dodd","year":"2015","journal-title":"Oncogene"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9375","article-title":"PI3K\/Akt and HIF-1 signaling pathway in hypoxia-ischemia","volume":"18","author":"Zhang","year":"2018","journal-title":"Mol Med Rep"},{"key":"B81","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.3390\/ijms21249739","article-title":"The roles of matrix metalloproteinases and their inhibitors in human diseases","volume":"21","author":"Cabral-Pacheco","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0273","article-title":"CXCR4-mediated glioma tumor tracking by bone marrow-derived neural progenitor\/stem cells","volume":"8","author":"Xu","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00159-4","article-title":"Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities","volume":"2","author":"Garofano","year":"2021","journal-title":"Nat Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1158\/0008-5472.CAN-23-2552","article-title":"Deuterium metabolic imaging differentiates glioblastoma metabolic subtypes and detects early response to chemoradiotherapy","volume":"84","author":"Low","year":"2024","journal-title":"Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/nu14051007","article-title":"Effects of the ketogenic diet in the treatment of gliomas: A systematic review","volume":"14","author":"Sarga\u00e7o","year":"2022","journal-title":"Nutrients"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.3390\/nu14183851","article-title":"Ketogenic diet in the treatment of gliomas and glioblastomas","volume":"14","author":"Dal Bello","year":"2022","journal-title":"Nutrients"},{"key":"B87","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-021-00831-w","article-title":"Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations","volume":"7","author":"Zhu","year":"2022","journal-title":"Signal Transduction Targeting Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab"},{"key":"B89","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/brainsci8080148","article-title":"The expanding role of ketogenic diets in adult neurological disorders","volume":"8","author":"McDonald","year":"2018","journal-title":"Brain Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2020.1847030","article-title":"Could ketogenic diet \u2018starve\u2019 cancer? Emerging evidence","volume":"62","author":"Barrea","year":"2022","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s42003-019-0455-x","article-title":"Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma","volume":"2","author":"Mukherjee","year":"2019","journal-title":"Commun Biol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1743-7075-7-74","article-title":"The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma","volume":"7","author":"Stafford","year":"2010","journal-title":"Nutr Metab"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2017.04.018","article-title":"Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism","volume":"12","author":"Kalyanaraman","year":"2017","journal-title":"Redox Biol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1758835919853958","DOI":"10.1177\/1758835919853958","article-title":"Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study","volume":"11","author":"van der Louw","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2364-x","article-title":"Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study","volume":"132","author":"Artzi","year":"2017","journal-title":"J Neurooncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2016.00122","article-title":"Tumor metabolism, the ketogenic diet and \u03b2-hydroxybutyrate: novel approaches to adjuvant brain tumor therapy","volume":"9","author":"Woolf","year":"2016","journal-title":"Front Mol Neurosci"},{"key":"B98","doi-asserted-by":"publisher","first-page":"100677","DOI":"10.1016\/j.bj.2023.100677","article-title":"Impact of fasting & ketogenic interventions on the NLRP3 inflammasome: A narrative review","volume":"47","author":"Neudorf","year":"2024","journal-title":"Biomed J"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2022.2054935","article-title":"Could very low-calorie ketogenic diets turn off low grade inflammation in obesity? Emerging evidence","volume":"63","author":"Barrea","year":"2023","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B100","doi-asserted-by":"publisher","first-page":"14564","DOI":"10.3390\/ijms232314564","article-title":"Ketone bodies as metabolites and signalling molecules at the crossroad between inflammation and epigenetic control of cardiometabolic disorders","volume":"23","author":"Bendridi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.3390\/ijms24043102","article-title":"The ketogenic diet and neuroinflammation: the action of beta-hydroxybutyrate in a microglial cell line","volume":"24","author":"Polito","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.11.065","article-title":"Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation","volume":"145","author":"Maalouf","year":"2007","journal-title":"Neuroscience"},{"key":"B103","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/antiox7050063","article-title":"Anti-oxidant and anti-inflammatory activity of ketogenic diet: new perspectives for neuroprotection in alzheimer\u2019s disease","volume":"7","author":"Pinto","year":"2018","journal-title":"Antioxid Basel Switz"},{"key":"B104","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.3390\/nu16234002","article-title":"Does the ketogenic diet mediate inflammation markers in obese and overweight adults? A systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Rondanelli","year":"2024","journal-title":"Nutrients"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3390\/cancers15051519","article-title":"Metabolic barriers to glioblastoma immunotherapy","volume":"15","author":"Choudhary","year":"2023","journal-title":"Cancers"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/cancers17111881","article-title":"The metabolic orchestration of immune evasion in glioblastoma: from molecular perspectives to therapeutic vulnerabilities","volume":"17","author":"Medikonda","year":"2025","journal-title":"Cancers"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112945","article-title":"Involvement of the kynurenine pathway in human glioma pathophysiology","volume":"9","author":"Adams","year":"2014","journal-title":"PLoS One"},{"key":"B108","doi-asserted-by":"publisher","first-page":"105363","DOI":"10.1016\/j.neuint.2022.105363","article-title":"The tryptophan metabolism, kynurenine pathway and oxidative stress - implications for glioma pathobiology","volume":"158","author":"Obara-Michlewska","year":"2022","journal-title":"Neurochem Int"},{"key":"B109","doi-asserted-by":"publisher","first-page":"189343","DOI":"10.1016\/j.bbcan.2025.189343","article-title":"Targeting the kynurenine pathway in gliomas: Insights into pathogenesis, therapeutic targets, and clinical advances","volume":"1880","author":"Krupa","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41467-023-37170-z","article-title":"Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR\/PPAR\u03b3 signaling axis","volume":"14","author":"Kesarwani","year":"2023","journal-title":"Nat Commun"},{"key":"B111","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12885-016-2337-7","article-title":"Enhanced immunity in a mouse model of Malignant glioma is mediated by a therapeutic ketogenic diet","volume":"16","author":"Lussier","year":"2016","journal-title":"BMC Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.3390\/cancers14225550","article-title":"The influence of the ketogenic diet on the immune tolerant microenvironment in glioblastoma","volume":"14","author":"Kesarwani","year":"2022","journal-title":"Cancers"},{"key":"B113","doi-asserted-by":"publisher","first-page":"21064","DOI":"10.1038\/s41598-025-06675-6","article-title":"A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma","volume":"15","author":"Amaral","year":"2025","journal-title":"Sci Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00390","article-title":"Exploring the feasibility and effects of a ketogenic diet in patients with CNS Malignancies: A retrospective case series","volume":"14","author":"Panhans","year":"2020","journal-title":"Front Neurosci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2018.10.024","article-title":"Treatment of Malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies","volume":"38","author":"Noorlag","year":"2019","journal-title":"Clin Nutr Edinb. Scotl"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.06.021","article-title":"ERGO2: A prospective, randomized trial of calorie-restricted ketogenic diet and fasting in addition to reirradiation for Malignant glioma","volume":"108","author":"Voss","year":"2020","journal-title":"Int J Radiat. Oncol Biol Phys"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101470","article-title":"Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme","volume":"208","author":"Wolf","year":"2011","journal-title":"J Exp Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1186\/s12967-025-06897-2","article-title":"Phosphofructokinase-1 redefined: a metabolic hub orchestrating cancer hallmarks through multi-dimensional control networks","volume":"23","author":"Yuan","year":"2025","journal-title":"J Transl Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.molcel.2018.03.018","article-title":"EGFR-phosphorylated platelet isoform of phosphofructokinase 1 promotes PI3K activation","volume":"70","author":"Lee","year":"2018","journal-title":"Mol Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1039\/D1MD00045D","article-title":"Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents","volume":"12","author":"Rathod","year":"2021","journal-title":"RSC Med Chem"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057610","article-title":"Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma","volume":"8","author":"Mukherjee","year":"2013","journal-title":"PLoS One"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101271","article-title":"Epigenetic silencing of miR-338 facilitates glioblastoma progression by de-repressing the pyruvate kinase M2-\u03b2-catenin axis","volume":"9","author":"Han","year":"2017","journal-title":"Aging"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq080","article-title":"Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells","volume":"12","author":"Kefas","year":"2010","journal-title":"Neuro-Oncol."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3514","article-title":"PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a\/c-Myc\/hnRNPA1 feedback loop","volume":"6","author":"Luan","year":"2015","journal-title":"Oncotarget"},{"key":"B125","doi-asserted-by":"publisher","first-page":"108029","DOI":"10.1016\/j.bioorg.2024.108029","article-title":"Development of novel tetrazole-based pyruvate kinase M2 inhibitors targeting U87MG glioblastoma cells","volume":"154","author":"Chowdhury","year":"2025","journal-title":"Bioorganic Chem"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3691","article-title":"An overview of structure, function, and regulation of pyruvate kinases","volume":"28","author":"Schormann","year":"2019","journal-title":"Protein Sci Publ. Protein Soc"},{"key":"B127","doi-asserted-by":"publisher","first-page":"14517","DOI":"10.1038\/s41598-018-31615-y","article-title":"Shikonin inhibits tumor growth in mice by suppressing pyruvate kinase M2-mediated aerobic glycolysis","volume":"8","author":"Zhao","year":"2018","journal-title":"Sci Rep"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.926945","article-title":"Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035571","article-title":"Non-metabolic enzyme function of PKM2 in hepatocellular carcinoma: A review","volume":"102","author":"Zhang","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.137","article-title":"Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2","volume":"30","author":"Chen","year":"2011","journal-title":"Oncogene"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00993","article-title":"Dimethylaminomicheliolide (DMAMCL) suppresses the proliferation of glioblastoma cells via targeting pyruvate kinase 2 (PKM2) and rewiring aerobic glycolysis","volume":"9","author":"Guo","year":"2019","journal-title":"Front Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"128539","DOI":"10.1016\/j.bmcl.2022.128539","article-title":"Boronic acid derivative activates pyruvate kinase M2 indispensable for redox metabolism in oral cancer cells","volume":"59","author":"Rihan","year":"2022","journal-title":"Bioorg. Med Chem Lett"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1060","article-title":"Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis","volume":"8","author":"Anastasiou","year":"2012","journal-title":"Nat Chem Biol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.583217","article-title":"The implications of PDK1\u20134 on tumor energy metabolism, aggressiveness and therapy resistance","volume":"10","author":"Atas","year":"2020","journal-title":"Front Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"8201079","DOI":"10.1155\/2019\/8201079","article-title":"Dichloroacetate (DCA) and cancer: an overview towards clinical applications","volume":"2019","author":"Tataranni","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0047-4","article-title":"Phase 1 trial of dichloroacetate (DCA) in adults with recurrent Malignant brain tumors","volume":"32","author":"Dunbar","year":"2014","journal-title":"Invest. New Drugs"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000677","article-title":"Metabolic modulation of glioblastoma with dichloroacetate","volume":"2","author":"Michelakis","year":"2010","journal-title":"Sci Transl Med 2 31ra34"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.320028","article-title":"Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications","volume":"287","author":"Morfouace","year":"2012","journal-title":"J Biol Chem"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e70120","DOI":"10.1002\/mco2.70120","article-title":"Glutamine metabolism: molecular regulation, biological functions, and diseases","volume":"6","author":"Kumar","year":"2025","journal-title":"MedComm"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2453","article-title":"Glutamate release by primary brain tumors induces epileptic activity","volume":"17","author":"Buckingham","year":"2011","journal-title":"Nat Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2012748118","article-title":"A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer","volume":"118","author":"Xu","year":"2021","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1112495109","article-title":"Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism","volume":"109","author":"Cassago","year":"2012","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414056112","article-title":"Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells","volume":"112","author":"Stalnecker","year":"2015","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14188","article-title":"A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR\/ERK signaling pathway","volume":"8","author":"Han","year":"2017","journal-title":"Oncotarget"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78239","article-title":"Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment","volume":"125","author":"Tanaka","year":"2015","journal-title":"J Clin Invest"},{"key":"B146","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41420-020-0258-3","article-title":"A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity","volume":"6","author":"Koch","year":"2020","journal-title":"Cell Death Discov"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29873","article-title":"Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells","volume":"138","author":"Kahlert","year":"2016","journal-title":"Int J Cancer"},{"key":"B148","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40170-024-00364-0","article-title":"Glutaminolysis is associated with mitochondrial pathway activation and can be therapeutically targeted in glioblastoma","volume":"12","author":"Miki","year":"2024","journal-title":"Cancer Metab"},{"key":"B149","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cbpa.2021.01.006","article-title":"Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment","volume":"62","author":"Shen","year":"2021","journal-title":"Curr Opin Chem Biol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3390\/pharmaceutics13020295","article-title":"Augmented therapeutic potential of glutaminase inhibitor CB839 in glioblastoma stem cells using gold nanoparticle delivery","volume":"13","author":"Giesen","year":"2021","journal-title":"Pharmaceutics"},{"key":"B151","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/cancers15020531","article-title":"Metabolic adjustments following glutaminase inhibition by CB-839 in glioblastoma cell lines","volume":"15","author":"De Los Santos-Jim\u00e9nez","year":"2023","journal-title":"Cancers"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting glutamine metabolism as a therapeutic strategy for cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp Mol Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15455","article-title":"Mitochondrial VDAC1-based peptides: Attacking oncogenic properties in glioblastoma","volume":"8","author":"Shteinfer-Kuzmine","year":"2017","journal-title":"Oncotarget"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now297","article-title":"VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties","volume":"19","author":"Arif","year":"2017","journal-title":"Neuro-Oncol."},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.9","article-title":"Silencing VDAC1 expression by siRNA inhibits cancer cell proliferation and tumor growth in vivo","volume":"3","author":"Arif","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"B156","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41419-024-06904-2","article-title":"Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme","volume":"15","author":"Bou-Gharios","year":"2024","journal-title":"Cell Death Dis"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4952","article-title":"Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches","volume":"12","author":"Huang","year":"2016","journal-title":"Oncol Lett"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy015","article-title":"Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study","volume":"20","author":"Brenner","year":"2018","journal-title":"Neuro-Oncol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.3390\/cancers15092613","article-title":"The role of hypoxia and cancer stem cells in development of glioblastoma","volume":"15","author":"Shi","year":"2023","journal-title":"Cancers"},{"key":"B161","doi-asserted-by":"publisher","first-page":"7632","DOI":"10.1038\/s41598-021-84331-5","article-title":"Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2025.1584407","article-title":"Hyperbaric oxygen promotes both the proliferation and chemosensitization of glioblastoma cells by inhibiting HIF1\u03b1\/HIF2\u03b1-ABCG2","volume":"18","author":"Gong","year":"2025","journal-title":"Front Mol Neurosci"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.886603","article-title":"Hyperbaric oxygen therapy as a complementary treatment in glioblastoma-A scoping review","volume":"13","author":"Alpuim Costa","year":"2022","journal-title":"Front Neurol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12935-025-03823-w","article-title":"HIF-1\u03b1 and HIF-2\u03b1: synergistic regulation of glioblastoma Malignant progression during hypoxia and apparent chemosensitization in response to hyperbaric oxygen","volume":"25","author":"Wang","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.12.070","article-title":"Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results","volume":"82","author":"Ogawa","year":"2012","journal-title":"Int J Radiat. Oncol Biol Phys"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrw105","article-title":"Radiotherapy using IMRT boosts after hyperbaric oxygen therapy with chemotherapy for glioblastoma","volume":"58","author":"Yahara","year":"2017","journal-title":"J Radiat. Res (Tokyo)"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.643469","article-title":"Role of hyperbaric oxygenation plus hypofractionated stereotactic radiotherapy in recurrent high-grade glioma","volume":"11","author":"Arpa","year":"2021","journal-title":"Front Oncol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-019-02837-x","article-title":"Noscapine, a non-addictive opioid and microtubule-inhibitor in potential treatment of glioblastoma","volume":"44","author":"Altinoz","year":"2019","journal-title":"Neurochem Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0360","article-title":"Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth","volume":"10","author":"Landen","year":"2004","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.surneu.2005.06.024","article-title":"Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro","volume":"65","author":"Altinoz","year":"2006","journal-title":"Surg Neurol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3892\/IJO.28.5.1121","article-title":"Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug","volume":"28","author":"Newcomb","year":"2006","journal-title":"Int J Oncol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2013.40","article-title":"Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth","volume":"34","author":"Qi","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3390\/cancers12061570","article-title":"Src inhibitors pyrazolo[3,4-d]pyrimidines, si306 and pro-si306, inhibit focal adhesion kinase and suppress human glioblastoma invasion","volume":"12","author":"Ne\u0161ovi\u0107","year":"2020","journal-title":"In Vitro In Vivo. Cancers"},{"key":"B174","doi-asserted-by":"publisher","first-page":"10496","DOI":"10.3390\/ijms221910496","article-title":"Disulfiram sensitizes a therapeutic-resistant glioblastoma to the TGF-\u03b2 Receptor inhibitor","volume":"22","author":"Liu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B175","article-title":"Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results","volume":"32","author":"Scaringi","year":"2012","journal-title":"Anticancer Res"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2011.12.028","article-title":"& Wang, Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme","volume":"19","author":"Zhang","year":"2012","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.961014","article-title":"Bevacizumab combined with re-irradiation in recurrent glioblastoma","volume":"12","author":"She","year":"2022","journal-title":"Front Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1014480108","article-title":"Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma","volume":"108","author":"Keunen","year":"2011","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0575","article-title":"Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy","volume":"15","author":"Lucio-Eterovic","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1712576\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T05:26:00Z","timestamp":1765344360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1712576\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":180,"alternative-id":["10.3389\/fonc.2025.1712576"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1712576","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1712576"}}